|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||62.98|
|Expense Ratio (net)||0.06%|
We highlight five ETFs & stocks that have recently seen their rank surging to the top hierarchy Zacks Rank #1 (Strong Buy).
Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.
In 1Q17, Zoetis (ZTS) managed to earn $615 million as revenues from international markets, which represents a YoY growth of around 8%.